medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2005, Number 4

<< Back Next >>

Rev Mex Oftalmol 2005; 79 (4)

Severity of retinopathy of prematurity and oxygen administration.

Nájera-Covarrubias MA, López-Díaz BEC, Wright K

Language: Spanish
References: 49
Page: 201-205
PDF size: 198.09 Kb.


ABSTRACT

Purpose: To determine whether curtailment of supplemental oxygen reduces the incidence of severe retinopathy of prematurity (ROP) and need for laser.
Methods: Retrospective study of preemies ‹1.500 g comparing data with VON and Cryo-Rop groups.
Results: A total of 488 preemies with average gestational age of 28weeks, average birth weight: 1.009 g. After curtailment of SpO2 (85-95%) the incidence of severe significantly decreased (12.5% vs. 4%, p=0.0077), also the need for laser diminished (7.5% vs. 0%, p=00.0047). Meanwhile, VON was stable: (Severe ROP: 10.2% vs. 10.4%, p=0.9769, and laser ROP: 5.5% vs. 6.25%, p=0.8112). Infant survival and systemic outcomes improved.
Conclusions: Severity of ROP can be reduced by early curtailment of supplemental oxygen without compromising systemic outcomes.


REFERENCES

  1. 1. Ben Sira I, Nissenkorn I, Kremer I. Retinopathy of prematurity. Surv Ophthalmol 1988; 33:1-16.

  2. 2. Good WV, Gendron RL. Retinopathy of prematurity. Ophthalmol Clin North Am 2001; 14:513-9.

  3. 3. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML y cols. Childhood blindness. J Aapos 1999; 3:26-32.

  4. 4. An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984; 102:1130-4.

  5. 5. Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2-year outcome—structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1993; 111:339-44.

  6. 6. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996; 114:417-24.

  7. 7. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 2002; 120:595-9.

  8. 8. Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C y cols. School-age outcomes in children with birth weights under 750 g. N Engl J Med 1994; 331:753-9.

  9. 9. Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E y cols. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002; 346:149-57.

  10. 10. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL y cols. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991; 98:1628-40.

  11. 11. Phillips J, Christiansen SP, Ware G, Landers S, Kirby RS. Ocular morbidity in very low birth-weight infants with intraventricular hemorrhage. Am J Ophthalmol 1997; 123:218-23.

  12. 12. Tasman W. The natural history of active retinopathy of prematurity. Ophthalmology 1984; 91:1499-503.

  13. 13. Vyas J, Field D, Draper ES, Woodruff G, Fielder AR y cols. Severe retinopathy of prematurity and its association with different rates of survival in infants of less than 1251 g birth weight. Arch Dis Child Fetal Neonatal Ed 2000; 82:F145-9.

  14. 14. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988; 106:471-9.

  15. 15. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990; 108:195-204.

  16. 16. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119:1110-8.

  17. 17. Connolly BP, Ng EY, McNamara JA, Regillo CD, Vander JF y cols. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109:936-41.

  18. 18. Ng EY, Connolly BP, McNamara JA, Regillo CD, Vander JF y cols. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109:928-34; discussion 35.

  19. 19. Phelps DL. Vision loss due to retinopathy of prematurity. Lancet 1981; 1:606.

  20. 20. Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States 1979. Pediatrics 1981; 67:924-5.

  21. 21. Terry TL. Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind each crystalline lens: I. Preliminary report. Am J Ophthalmol 1942; 25:203.

  22. 22. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants, II: report of cases-clinical aspects. Arch Ophthalmol 1943; 29:36-53.

  23. 23. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust 1951; 2:48.

  24. 24. Patz A, Hoech L, de la Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia: I. Nursery observations. Am J Ophthalmol 1952; 35:1248.

  25. 25. Lanman J, Guy L, Dancis J. Retrolental fibroplasia and oxygen therapy. JAMA 1954; 155:223.

  26. 26. Kinsey V. Retrolental fibroplasia: Cooperative study of retrolental fibroplasia and the use of oxygen. Trans Assoc Acad Ophthalmol Otolaryngol 1955; 59:15.

  27. 27. Patz A. Mead Johnson award address: The role of oxygen in retrolental fibroplasia. Pediatrics 1957; 19:504.

  28. 28. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114:1219-28.

  29. 29. Cross KW. Cost of preventing retrolental fibroplasia? Lancet 1973; 2:954-6.

  30. 30. James S, Lanman JT. History of oxygen therapy and retrolental fibroplasia. Prepared by the American Academy of Pediatrics, Committee on Fetus and Newborn with the collaboration of special consultants. Pediatrics 1976; 57:591-642.

  31. 31. Flynn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W y cols. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326:1050-4.

  32. 32. Chan-Ling T, Stone J. Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci 1992; 33:2148-59.

  33. 33. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci 1995; 36:2063-70.

  34. 34. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors 1998; 16:1-9.

  35. 35. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84:F106-10.

  36. 36. Chan-Ling T, Stone J. Retinopathy of Prematurity: origins in the architecture of the retina. Progress in retinal research 1993; 12:155-78.

  37. 37. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that ‘physiological hypoxia’ is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995; 36:1201-14.

  38. 38. Stone J, Itin A, Alon T, Pe’er J, Gnessin H y cols. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15:4738-47.

  39. 39. Stone J, Chan-Ling T, Pe’er J, Itin A, Gnessin H y cols. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 37:290-9.

  40. 40. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41:1217-28.

  41. 41. Supplemental Therapeutic Oxygen for Prethreshold Retino-

  42. pathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105:295-310.

  43. 42. Flynn JT, Bancalari E. On supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. J Aapos 2000; 4:65-6.

  44. 43. Hay WW, Jr., Bell EF. Oxygen therapy, oxygen toxicity, and the STOP-ROP trial. Pediatrics 2000; 105:424-5.

  45. 44. Tailoi CL, Gock B, Stone J. Supplemental oxygen therapy. Basis for noninvasive treatment of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1995; 36:1215-30.

  46. 45. Chan-Ling T, Tout S, Hollander H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1992; 33:2128-47.

  47. 46. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F y cols. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276:1706-9.

  48. 47. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F y cols. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390-5.

  49. 48. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL y cols. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98:5804-8.




2020     |     www.medigraphic.com